Home » Healthcare » Monoclonal Antibodies Therapeutics Market

Monoclonal Antibodies Therapeutics Market By Sources (Humanized mAbs, Chimeric mAbs, Others); By Therapeutic Area (Oncology, Autoimmune & Inflammatory Diseases, Infectious Diseases, Cardiovascular & Metabolic Disorders, Neurological Disorders, Others); By Route of Administration (Subcutaneous (SC), Intravenous (IV), Others); By Sales Channel (Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, Online Pharmacies) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Monoclonal Antibodies Therapeutics Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-10-23
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Monoclonal Antibodies Therapeutics Market

Summary
Table Of Content
Request Free Sample

Market Overview:

Monoclonal Antibodies Therapeutics Market size was valued at USD 122,396.5 Million in 2018 and USD 248,032.3 Million in 2024, and is anticipated to reach USD 667,444.1 Million by 2032, at a CAGR of 13.29% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Monoclonal Antibodies Therapeutics Market Size 2024	USD 248,032.3 Million
Monoclonal Antibodies Therapeutics Market, CAGR	13.29%
Monoclonal Antibodies Therapeutics Market Size 2032	USD 667,444.1 Million

The Monoclonal Antibodies Therapeutics Market is dominated by key players such as F. Hoffmann-La Roche Ltd, Sanofi, Abbvie Inc., Bristol Myers Squibb, Novartis AG, AstraZeneca, Amgen Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and Johnson & Johnson Services, Inc. These companies maintain leadership through strategic initiatives including new product launches, collaborations, acquisitions, and robust R&D investments focused on innovative therapies like humanized and bispecific antibodies. North America emerges as the leading region, capturing a 31% market share in 2024, driven by advanced healthcare infrastructure, high adoption of targeted therapies, and growing prevalence of cancer and autoimmune disorders. The U.S. serves as the primary contributor, benefiting from early adoption of novel monoclonal antibody treatments, strong regulatory support, and established biopharmaceutical networks, solidifying the region’s dominant position in the global market.

Monoclonal Antibodies Therapeutics Market size

Market Insights

The Monoclonal Antibodies Therapeutics Market was valued at USD 248,032.3 Million in 2024 and is projected to reach USD 667,444.1 Million by 2032, growing at a CAGR of 13.29%. Humanized mAbs dominate the market with a 52% share, followed by chimeric mAbs at 32%, and other mAbs at 16%.
Market growth is driven by rising demand for targeted therapies, increasing prevalence of chronic and autoimmune diseases, and technological advancements in antibody engineering improving therapeutic efficacy.
Key trends include the shift toward subcutaneous self-administration, expansion of homecare therapies, and increased focus on oncology and rare diseases, supporting patient convenience and broader adoption.
Competitive landscape features leading players such as F. Hoffmann-La Roche Ltd, Sanofi, Abbvie Inc., Bristol Myers Squibb, Novartis AG, AstraZeneca, Amgen Inc., and Johnson & Johnson, leveraging R&D, strategic partnerships, and biosimilar development to sustain growth.
North America leads with a 31% market share, followed by Europe at 29% and Asia Pacific at 22%, while Latin America, Middle East, and Africa contribute smaller shares, driven by regional healthcare infrastructure and adoption trends.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Segmentation Analysis:

By Sources:

The monoclonal antibodies therapeutics market by sources is primarily segmented into Humanized mAbs, Chimeric mAbs, and Others. Humanized mAbs dominate the market, accounting for 52% share, driven by their higher efficacy, reduced immunogenicity, and widespread adoption in oncology and autoimmune therapies. Chimeric mAbs hold a significant share of around 32%, benefiting from established clinical applications and ongoing pipeline developments. The remaining 16% is contributed by other mAbs, which include fully murine and novel engineered antibodies. Increasing demand for targeted therapies and the rising prevalence of chronic diseases are key drivers across all source segments.

For instance, Genentech’s Obinutuzumab, a humanized anti-CD20 antibody, has gained FDA approval for chronic lymphocytic leukemia treatment due to its enhanced efficacy and safety profile.

By Therapeutic Area:

Oncology leads the monoclonal antibodies therapeutics market by therapeutic area, capturing a dominant 45% share due to the growing incidence of cancers and the effectiveness of mAbs in targeted tumor therapy. Autoimmune and inflammatory diseases account for about 25%, supported by rising cases of rheumatoid arthritis, psoriasis, and multiple sclerosis. Infectious diseases contribute around 12%, fueled by advancements in antibody-based antiviral and antibacterial therapies. Cardiovascular and metabolic disorders, neurological disorders, and other indications collectively hold the remaining 18%, driven by expanding indications and ongoing clinical research.

For instance, Rituxan (rituximab), developed by Genentech and IDEC Pharmaceuticals, shows up to a 72% overall response rate in follicular non-Hodgkin’s lymphoma patients, significantly improving remission durations.

By Route of Administration:

The market by route of administration is primarily divided into Subcutaneous (SC), Intravenous (IV), and Others. Subcutaneous administration dominates with a 55% market share, favored for its convenience, reduced hospital visits, and suitability for self-administration in chronic conditions. Intravenous administration holds around 38% share, primarily used for hospital-based therapies requiring precise dosing and rapid therapeutic effects. The remaining 7% includes emerging routes such as intramuscular and inhalation-based delivery. Growth is propelled by patient preference for minimally invasive methods and the increasing adoption of homecare treatment models.

Key Growth Drivers

Rapid Adoption of Targeted Therapies

The increasing preference for targeted therapies is a primary growth driver in the monoclonal antibodies therapeutics market. Humanized and chimeric antibodies offer precise mechanisms of action, reducing off-target effects and improving patient outcomes, particularly in oncology and autoimmune disorders. This has led to accelerated adoption in clinical practice and expanded treatment pipelines. Rising awareness among healthcare professionals and patients regarding the benefits of personalized therapy further strengthens market demand, encouraging biopharmaceutical companies to invest in research and develop advanced monoclonal antibody products.

For instance, Leadgene Biomedical developed humanized monoclonal antibodies 2E8 and 33D2, demonstrating strong antigen binding and promising therapeutic efficacy in preclinical studies.

Rising Prevalence of Chronic and Autoimmune Diseases

The growing burden of chronic illnesses and autoimmune disorders is fueling monoclonal antibodies therapeutics demand. Conditions such as rheumatoid arthritis, psoriasis, multiple sclerosis, and various cancers require long-term, targeted interventions, positioning mAbs as preferred treatment options. Increasing life expectancy, lifestyle changes, and the prevalence of age-related disorders further intensify market adoption. Pharmaceutical companies are responding with new formulations, dosage forms, and combination therapies to address these conditions effectively, driving revenue growth and expanding the overall patient base.

For instance, in multiple sclerosis, mAbs like alemtuzumab and rituximab have revolutionized treatment by offering higher clinical potency and impacting disease progression more robustly than previous treatments.

Technological Advancements and Biopharmaceutical Innovations

Advances in biotechnology and antibody engineering have significantly propelled the market. Innovations such as bispecific antibodies, antibody-drug conjugates, and fully humanized antibodies improve therapeutic efficacy while minimizing side effects. Enhanced manufacturing techniques and optimized production processes have reduced costs and increased scalability. Additionally, integration of artificial intelligence and bioinformatics accelerates drug discovery and clinical trials. These technological developments not only support the launch of next-generation therapies but also create opportunities for expanding monoclonal antibody applications across multiple disease areas.

Key Trends & Opportunities

Rising Focus on Oncology and Rare Diseases

The monoclonal antibodies market is witnessing a trend toward targeting oncology and rare diseases. With cancer incidence climbing globally and a growing emphasis on precision medicine, pharmaceutical companies are developing innovative mAbs for specific tumor types and genetic profiles. Similarly, orphan diseases with limited treatment options present lucrative opportunities, as regulatory incentives and faster approvals encourage new product development. This trend strengthens research pipelines, diversifies therapeutic applications, and drives market expansion across regions with high unmet medical needs.

For instance, Seattle Genetics developed brentuximab vedotin, a monoclonal antibody-drug conjugate that delivers chemotherapy directly to Hodgkin lymphoma cells, improving treatment specificity and outcomes.

Expansion of Self-Administration and Homecare Therapies

The shift toward subcutaneous formulations and self-administration is creating new market opportunities. Patients prefer convenient home-based treatments over hospital visits, particularly for chronic conditions such as autoimmune disorders. This trend reduces healthcare costs, improves treatment adherence, and enhances patient quality of life. Pharmaceutical companies are investing in prefilled pens, auto-injectors, and user-friendly delivery devices, enabling broader adoption of monoclonal antibodies and supporting revenue growth, especially in developed and emerging markets where patient-centric care is increasingly prioritized.

For instance, the BD Libertas™ wearable injector system supports large-volume subcutaneous delivery for monoclonal antibodies, enabling patients to self-administer doses comfortably at home, which enhances patient-centric care and reduces healthcare visits.

Key Challenges

High Cost of Therapy and Limited Accessibility

The monoclonal antibodies therapeutics market faces challenges due to the high cost of treatment, which restricts patient access, particularly in low- and middle-income countries. Manufacturing complexity, specialized storage, and rigorous clinical development contribute to premium pricing. This financial burden limits widespread adoption and can slow market growth despite clinical demand. Payers and healthcare systems are increasingly scrutinizing cost-effectiveness, forcing manufacturers to explore pricing strategies, biosimilars, and partnerships to improve affordability while maintaining profitability.

Stringent Regulatory Approvals and Clinical Trial Requirements

Strict regulatory frameworks pose significant challenges for monoclonal antibody development. Extensive clinical trials, safety assessments, and adherence to regional guidelines delay product launches and increase R&D expenditures. Differences in approval processes across regions create additional complexity for global market expansion. These regulatory hurdles require substantial investment in documentation, compliance, and pharmacovigilance, which can impact the timeline and profitability of new therapies. Companies must strategically navigate these requirements to ensure timely approvals and mitigate risks associated with market entry.

Regional Analysis

North America

North America leads the monoclonal antibodies therapeutics market with a market share of 31% in 2024. Valued at USD 47,061.46 million in 2018, the market expanded to USD 93,933.37 million in 2024 and is projected to reach USD 247,621.77 million by 2032, growing at a CAGR of 13.00%. Strong healthcare infrastructure, high adoption of targeted therapies, and increasing prevalence of cancer and autoimmune disorders drive market growth. The U.S. dominates the region due to advanced R&D, established biopharmaceutical companies, and early adoption of innovative monoclonal antibody therapies.

Europe

Europe holds a significant market share of around 29% in 2024. The market grew from USD 35,091.08 million in 2018 to USD 70,504.95 million in 2024 and is anticipated to reach USD 187,551.80 million by 2032, at a CAGR of 13.13%. Growth is driven by increasing incidence of cancer and autoimmune diseases, supportive regulatory frameworks, and strong healthcare expenditure. Germany, France, and the UK are key contributors, with expanding research pipelines and rising patient awareness enhancing adoption of monoclonal antibody therapeutics across the region.

Asia Pacific

Asia Pacific represents a rapidly growing segment, with a market share of 22% in 2024. The market increased from USD 21,896.73 million in 2018 to USD 45,871.80 million in 2024 and is projected to reach USD 128,816.72 million by 2032, at a CAGR of 13.89%. Growth is fueled by rising healthcare investments, increasing prevalence of chronic and infectious diseases, and growing awareness of monoclonal antibody therapies. China, Japan, and India are the largest contributors, supported by expanding healthcare infrastructure, improving affordability, and government initiatives to enhance patient access.

Latin America

Latin America holds a market share of 7% in 2024. The market grew from USD 10,721.93 million in 2018 to USD 22,195.35 million in 2024, and is expected to reach USD 61,404.86 million by 2032, at a CAGR of 13.68%. Brazil and Argentina dominate the region, driven by rising awareness, expanding healthcare infrastructure, and government support for advanced therapies. Increasing adoption of monoclonal antibody treatments for oncology and autoimmune disorders is propelling market growth, while improving reimbursement policies further facilitate patient access in key countries.

Middle East

The Middle East contributes a market share of 4% in 2024. Valued at USD 5,850.55 million in 2018, the market increased to USD 12,196.10 million in 2024 and is projected to reach USD 34,039.65 million by 2032, growing at a CAGR of 13.81%. Growth is driven by rising incidence of cancer and chronic diseases, increasing healthcare expenditure, and investments in advanced therapies. GCC countries and Israel are the largest contributors, with expanding specialty clinics and hospital networks facilitating the adoption of monoclonal antibody therapeutics across the region.

Africa

Africa represents a smaller but growing segment, holding a market share of 1.5% in 2024. The market grew from USD 1,774.75 million in 2018 to USD 3,330.72 million in 2024 and is projected to reach USD 8,009.33 million by 2032, at a CAGR of 11.70%. Growth is supported by increasing healthcare infrastructure, rising awareness of monoclonal antibody therapies, and government initiatives to improve access to advanced treatments. South Africa and Egypt are key contributors, with expanding hospital networks and partnerships with international biopharmaceutical companies facilitating market expansion.

Market Segmentations:

By Sources

Humanized mAbs
Chimeric mAbs
Others

By Therapeutic Area

Oncology
Autoimmune & Inflammatory Diseases
Infectious Diseases
Cardiovascular & Metabolic Disorders
Neurological Disorders
Others

By Route of Administration

Subcutaneous (SC)
Intravenous (IV)
Others

By Sales Channel

Hospital Pharmacies
Specialty Clinics
Retail Pharmacies
Online Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Competitive Landscape

The competitive landscape of the monoclonal antibodies therapeutics market includes key players such as F. Hoffmann-La Roche Ltd, Sanofi, Abbvie Inc., Bristol Myers Squibb, Novartis AG, AstraZeneca, Amgen Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and Johnson & Johnson Services, Inc. These companies dominate through strategic initiatives, including new product launches, collaborations, acquisitions, and pipeline expansions. Intense focus on R&D enables the development of innovative therapies such as humanized and bispecific antibodies, supporting differentiation in oncology, autoimmune, and infectious disease segments. Companies are also expanding global manufacturing capabilities and optimizing distribution networks to enhance market reach. Competitive pricing, biosimilar development, and regulatory compliance remain critical for sustaining growth. The market remains dynamic, driven by technological advancements and rising demand for targeted therapies, compelling players to continuously innovate and adapt to evolving therapeutic needs and regional market demands.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Hoffmann-La Roche Ltd
Sanofi
Abbvie Inc.
Bristol Myers Squibb Company
Novartis AG
AstraZeneca
Amgen Inc.
Eli Lilly and Company
Takeda Pharmaceutical Company Limited
Johnson & Johnson Services, Inc.

Recent Developments

In September 2025, Genmab acquired Merus for $8 billion, gaining access to the late-stage drug petosemtamab for head and neck cancer.
In October 2025, Merck KGaA announced the acquisition of JSR Life Sciences’ chromatography business to enhance its monoclonal antibody production capabilities.
In October 2025, Roche received FDA approval for its monoclonal antibody therapy Gazyva®/Gazyvaro® (obinutuzumab) for adults with active lupus nephritis undergoing standard treatment, featuring a new 90-minute infusion option for eligible patients.
In June 2025, Bio-Techne Corporation partnered with the U.S. Pharmacopeia (USP) to distribute USP monoclonal antibody reference standards alongside Bio-Techne’s analytical solutions, aiming to accelerate global monoclonal antibody product development.

Report Coverage

The research report offers an in-depth analysis based on Source, Therapeutic Area, Route of Administration, Sales Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The market is expected to witness sustained growth driven by rising demand for targeted therapies.
Expansion of monoclonal antibody applications in oncology and autoimmune diseases will continue to boost adoption.
Advances in antibody engineering, including bispecific and fully humanized mAbs, will enhance therapeutic efficacy.
Increasing preference for subcutaneous and self-administration routes will improve patient compliance and convenience.
Emerging markets in Asia Pacific, Latin America, and the Middle East will offer significant growth opportunities.
Pharmaceutical companies will intensify R&D investments to develop next-generation monoclonal antibody therapies.
Strategic partnerships, collaborations, and acquisitions will remain key growth strategies for market players.
Growing awareness and early diagnosis of chronic diseases will support market expansion.
Regulatory support and faster approval processes will accelerate the launch of innovative therapies.
Adoption of biosimilars will increase, improving accessibility and affordability for patients globally.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 : MONOCLONAL ANTIBODIES THERAPEUTICS MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

CHAPTER NO. 4 : KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Sources Categories

4.3 Therapeutic Area Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Sources, Therapeutic Area, Route of Administration, & Sales Channel Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1. Import Analysis By Region

6.1.1. Global Monoclonal Antibodies Therapeutics Market Import Revenue By Region

6.2. Export Analysis By Region

6.2.1. Global Monoclonal Antibodies Therapeutics Market Export Revenue By Region

CHAPTER NO. 7 : COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Monoclonal Antibodies Therapeutics Market: Company Market Share

7.2. Global Monoclonal Antibodies Therapeutics Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 : MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – BY SOURCES SEGMENT ANALYSIS

8.1. Monoclonal Antibodies Therapeutics Market Overview By Sources Segment

8.1.1. Monoclonal Antibodies Therapeutics Market Revenue Share By Sources

8.2. Humanized mAbs

8.3. Chimeric mAbs

8.4. Others

CHAPTER NO. 9 : MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – BY THERAPEUTIC AREA SEGMENT ANALYSIS

9.1. Monoclonal Antibodies Therapeutics Market Overview By Therapeutic Area Segment

9.1.1. Monoclonal Antibodies Therapeutics Market Revenue Share By Therapeutic Area

9.2. Oncology

9.3. Autoimmune & Inflammatory Diseases

9.4. Infectious Diseases

9.5. Cardiovascular & Metabolic Disorders

9.6. Neurological Disorders

9.7. Others

CHAPTER NO. 10 : MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – BY ROUTE OF ADMINISTRATION SEGMENT ANALYSIS

10.1. Monoclonal Antibodies Therapeutics Market Overview By Route of Administration Segment

10.1.1. Monoclonal Antibodies Therapeutics Market Revenue Share By Route of Administration

10.2. Subcutaneous (SC)

10.3. Intravenous (IV)

10.4. Others

CHAPTER NO. 11 : MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – BY SALES CHANNEL SEGMENT ANALYSIS

11.1. Monoclonal Antibodies Therapeutics Market Overview By Sales Channel Segment

11.1.1. Monoclonal Antibodies Therapeutics Market Revenue Share By Sales Channel

11.2. Hospital Pharmacies

11.3. Specialty Clinics

11.4. Retail Pharmacies

11.5. Online Pharmacies

CHAPTER NO. 12 : MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – REGIONAL ANALYSIS

12.1. Monoclonal Antibodies Therapeutics Market Overview By Region Segment

12.1.1. Global Monoclonal Antibodies Therapeutics Market Revenue Share By Region

12.1.2. Regions

12.1.3. Global Monoclonal Antibodies Therapeutics Market Revenue By Region

12.1.4. Sources

12.1.5. Global Monoclonal Antibodies Therapeutics Market Revenue By Sources

12.1.6. Therapeutic Area

12.1.7. Global Monoclonal Antibodies Therapeutics Market Revenue By Therapeutic Area

12.1.8. Route of Administration

12.1.9. Global Monoclonal Antibodies Therapeutics Market Revenue By Route of Administration

12.1.10. Sales Channel

12.1.11. Global Monoclonal Antibodies Therapeutics Market Revenue By Sales Channel

CHAPTER NO. 13 : NORTH AMERICA MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – COUNTRY ANALYSIS

13.1. North America Monoclonal Antibodies Therapeutics Market Overview By Country Segment

13.1.1. North America Monoclonal Antibodies Therapeutics Market Revenue Share By Region

13.2. North America

13.2.1. North America Monoclonal Antibodies Therapeutics Market Revenue By Country

13.2.2. Sources

13.2.3. North America Monoclonal Antibodies Therapeutics Market Revenue By Sources

13.2.4. Therapeutic Area

13.2.5. North America Monoclonal Antibodies Therapeutics Market Revenue By Therapeutic Area

13.2.6. Route of Administration

13.2.7. North America Monoclonal Antibodies Therapeutics Market Revenue By Route of Administration

13.2.8. Sales Channel

13.2.9. North America Monoclonal Antibodies Therapeutics Market Revenue By Sales Channel

13.3. U.S.

13.4. Canada

13.5. Mexico

CHAPTER NO. 14 : EUROPE MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – COUNTRY ANALYSIS

14.1. Europe Monoclonal Antibodies Therapeutics Market Overview By Country Segment

14.1.1. Europe Monoclonal Antibodies Therapeutics Market Revenue Share By Region

14.2. Europe

14.2.1. Europe Monoclonal Antibodies Therapeutics Market Revenue By Country

14.2.2. Sources

14.2.3. Europe Monoclonal Antibodies Therapeutics Market Revenue By Sources

14.2.4. Therapeutic Area

14.2.5. Europe Monoclonal Antibodies Therapeutics Market Revenue By Therapeutic Area

14.2.6. Route of Administration

14.2.7. Europe Monoclonal Antibodies Therapeutics Market Revenue By Route of Administration

14.2.8. Sales Channel

14.2.9. Europe Monoclonal Antibodies Therapeutics Market Revenue By Sales Channel

14.3. UK

14.4. France

14.5. Germany

14.6. Italy

14.7. Spain

14.8. Russia

14.9. Rest of Europe

CHAPTER NO. 15 : ASIA PACIFIC MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – COUNTRY ANALYSIS

15.1. Asia Pacific Monoclonal Antibodies Therapeutics Market Overview By Country Segment

15.1.1. Asia Pacific Monoclonal Antibodies Therapeutics Market Revenue Share By Region

15.2. Asia Pacific

15.2.1. Asia Pacific Monoclonal Antibodies Therapeutics Market Revenue By Country

15.2.2. Sources

15.2.3. Asia Pacific Monoclonal Antibodies Therapeutics Market Revenue By Sources

15.2.4. Therapeutic Area

15.2.5. Asia Pacific Monoclonal Antibodies Therapeutics Market Revenue By Therapeutic Area

15.2.6. Route of Administration

15.2.7. Asia Pacific Monoclonal Antibodies Therapeutics Market Revenue By Route of Administration

15.2.8. Sales Channel

15.2.9. Asia Pacific Monoclonal Antibodies Therapeutics Market Revenue By Sales Channel

15.3. China

15.4. Japan

15.5. South Korea

15.6. India

15.7. Australia

15.8. Southeast Asia

15.9. Rest of Asia Pacific

CHAPTER NO. 16 : LATIN AMERICA MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – COUNTRY ANALYSIS

16.1. Latin America Monoclonal Antibodies Therapeutics Market Overview By Country Segment

16.1.1. Latin America Monoclonal Antibodies Therapeutics Market Revenue Share By Region

16.2. Latin America

16.2.1. Latin America Monoclonal Antibodies Therapeutics Market Revenue By Country

16.2.2. Sources

16.2.3. Latin America Monoclonal Antibodies Therapeutics Market Revenue By Sources

16.2.4. Therapeutic Area

16.2.5. Latin America Monoclonal Antibodies Therapeutics Market Revenue By Therapeutic Area

16.2.6. Route of Administration

16.2.7. Latin America Monoclonal Antibodies Therapeutics Market Revenue By Route of Administration

16.2.8. Sales Channel

16.2.9. Latin America Monoclonal Antibodies Therapeutics Market Revenue By Sales Channel

16.3. Brazil

16.4. Argentina

16.5. Rest of Latin America

CHAPTER NO. 17 : MIDDLE EAST MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – COUNTRY ANALYSIS

17.1. Middle East Monoclonal Antibodies Therapeutics Market Overview By Country Segment

17.1.1. Middle East Monoclonal Antibodies Therapeutics Market Revenue Share By Region

17.2. Middle East

17.2.1. Middle East Monoclonal Antibodies Therapeutics Market Revenue By Country

17.2.2. Sources

17.2.3. Middle East Monoclonal Antibodies Therapeutics Market Revenue By Sources

17.2.4. Therapeutic Area

17.2.5. Middle East Monoclonal Antibodies Therapeutics Market Revenue By Therapeutic Area

17.2.6. Route of Administration

17.2.7. Middle East Monoclonal Antibodies Therapeutics Market Revenue By Route of Administration

17.2.8. Sales Channel

17.2.9. Middle East Monoclonal Antibodies Therapeutics Market Revenue By Sales Channel

17.3. GCC Countries

17.4. Israel

17.5. Turkey

17.6. Rest of Middle East

CHAPTER NO. 18 : AFRICA MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – COUNTRY ANALYSIS

18.1. Africa Monoclonal Antibodies Therapeutics Market Overview By Country Segment

18.1.1. Africa Monoclonal Antibodies Therapeutics Market Revenue Share By Region

18.2. Africa

18.2.1. Africa Monoclonal Antibodies Therapeutics Market Revenue By Country

18.2.2. Sources

18.2.3. Africa Monoclonal Antibodies Therapeutics Market Revenue By Sources

18.2.4. Therapeutic Area

18.2.5. Africa Monoclonal Antibodies Therapeutics Market Revenue By Therapeutic Area

18.2.6. Route of Administration

18.2.7. Africa Monoclonal Antibodies Therapeutics Market Revenue By Route of Administration

18.2.8. Sales Channel

18.2.9. Africa Monoclonal Antibodies Therapeutics Market Revenue By Sales Channel

18.3. South Africa

18.4. Egypt

18.5. Rest of Africa

CHAPTER NO. 19 : COMPANY PROFILES

19.1. F. Hoffmann-La Roche Ltd

19.1.1. Company Overview

19.1.2. Product Portfolio

19.1.3. Financial Overview

19.1.4. Recent Developments

19.1.5. Growth Strategy

19.1.6. SWOT Analysis

19.2. Sanofi

19.3. Abbvie Inc.

19.4. Bristol Myers Squibb Company

19.5. Novartis AG

19.6. AstraZeneca

19.7. Amgen Inc.

19.8. Eli Lilly and Company

19.9. Takeda Pharmaceutical Company Limited

19.10. Johnson & Johnson Services, Inc.

19.11. Other Key Players

Request A Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions:

What is the current market size for Monoclonal Antibodies Therapeutics Market, and what is its projected size in 2032?

The Monoclonal Antibodies Therapeutics Market is valued at USD 248,032.3 Million in 2024 and is projected to reach USD 667,444.1 Million by 2032.

At what Compound Annual Growth Rate is the Monoclonal Antibodies Therapeutics Market projected to grow between 2025 and 2032?

The Monoclonal Antibodies Therapeutics Market is expected to grow at a CAGR of 13.29% during the forecast period.

Which Monoclonal Antibodies Therapeutics Market segment held the largest share in 2024?

Humanized mAbs held the largest share of approximately 52% in the Monoclonal Antibodies Therapeutics Market in 2024.

What are the primary factors fueling the growth of the Monoclonal Antibodies Therapeutics Market?

The Monoclonal Antibodies Therapeutics Market is driven by rising demand for targeted therapies, increasing prevalence of chronic and autoimmune diseases, and technological advancements in antibody engineering.

Who are the leading companies in the Monoclonal Antibodies Therapeutics Market?

Key players in the Monoclonal Antibodies Therapeutics Market include F. Hoffmann-La Roche Ltd, Sanofi, Abbvie Inc., Bristol Myers Squibb, Novartis AG, AstraZeneca, Amgen Inc., Eli Lilly and Company

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports

Emergency Ambulance Vehicle Market

The Global Emergency Ambulance Vehicle Market size was valued at USD 16,212.77 million in 2018 to USD 21,446.85 million in 2024 and is anticipated to reach USD 31,490.74 million by 2032, at a CAGR of 4.58% during the forecast period.

Dopamine Agonists Market

The Dopamine Agonists market was valued at USD 1.4 billion in 2024 and is projected to reach USD 2.44 billion by 2032, growing at a CAGR of 7.2% during the forecast period.

U.S. Monoclonal Antibodies Therapeutics Market

The U.S. Monoclonal Antibodies Therapeutics Market was valued at USD 34,566.64 million in 2018 and grew to USD 67,605.19 million in 2024. The market is anticipated to reach USD 173,335.24 million by 2032, reflecting a robust compound annual growth rate (CAGR) of 12.2% during the forecast period.

Latin America Retail Pharmacy Market

The Latin America Retail Pharmacy Market size was valued at USD 54,202.26 million in 2018 to USD 65,793.78 million in 2024 and is anticipated to reach USD 83,665.54 million by 2032, at a CAGR of 2.84% during the forecast period.

Egypt In-Vitro Fertilization (IVF) Market

The Egypt In-Vitro Fertilization (IVF) Market size was valued at USD 328.41 million in 2018 to USD 521.36 million in 2024 and is anticipated to reach USD 947.89 million by 2032, at a CAGR of 7.23% during the forecast period.

Healthcare Simulation Market

Healthcare Simulation Market size was valued USD 3.04 billion in 2024 and is anticipated to reach USD 9.33 billion by 2032, at a CAGR of 15.04% during the forecast period.

Degenerative Disc Disease Treatment Market

The Degenerative Disc Disease Treatment market was valued at USD 1.8 billion in 2024 and is projected to reach USD 3.36 billion by 2032, growing at a CAGR of 8.1% during the forecast period.

Germany Compounding Pharmacies Market

Germany Compounding Pharmacies Market size was valued at USD 381.95 Million in 2018, growing to USD 535.21 Million in 2024, and is anticipated to reach USD 829.32 Million by 2032, at a CAGR of 5.24% during the forecast period.

Italy Compounding Pharmacies Market

Italy Compounding Pharmacies Market size was valued at USD 267.42 Million in 2018, growing to USD 379.23 Million in 2024, and is anticipated to reach USD 597.97 Million by 2032, at a CAGR of 5.45% during the forecast period.

Japan Compounding Pharmacies Market

Japan Compounding Pharmacies Market size was valued at USD 142.60 million in 2018 and increased to USD 221.90 million in 2024. The market is anticipated to reach USD 403.45 million by 2032, growing at a CAGR of 7.23% during the forecast period.

Glucose Biosensors Market

Glucose Biosensors Market size was valued USD 18.49 billion in 2024 and is anticipated to reach USD 28.16 billion by 2032, at a CAGR of 5.4% during the forecast period.

UK Psychometric Assessments Services Market

The UK Psychometric Assessments Services market size was valued at USD 210.20 million in 2018 and increased to USD 245.50 million in 2024. It is anticipated to reach USD 410.70 million by 2032, growing at a CAGR of 6.64% during the forecast period.

Licence Option

Single User

$4999

Multi User

$6999

Enterprise

$12999

Report delivery within 24 to 48 hours

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request A Free Sample

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample